TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2024-06-04
劉俊人Liu, Chun-Jen
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
-
jiun0924@gmail.com
發表文獻
74筆
41
Hong TC, Yang HC, Chen CL, Kao JH, Liu CJ, Chen MJ, Wang HY, Kuo YC, Yu LY, Hu KC. Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. PLoS One. 2020 Oct 13;15(10):e0240445. doi: 10.1371/journal.pone.0240445. PMID: 33048943; PMCID: PMC7553303.
42
Wen WH, Chen HL, Shih TT, Wu JF, Ni YH, Lee CN, Zhao LL, Lai MW, Mu SC, Tung YC, Hsu HY, Chang MH; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study)(‡). Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate. J Hepatol. 2020 Jun;72(6):1082-1087. doi: 10.1016/j.jhep.2020.01.021. Epub 2020 Feb 8. PMID: 32044401.
43
Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ, Chen PJ, Gaggar A, Suri V, Mücke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K, Liang TJ. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest. 2020 Jun 1;130(6):3205-3220. doi: 10.1172/JCI135616. PMID: 32163375; PMCID: PMC7259999.
44
Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Lin HC, Kao JH, Chuang WL. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020 Jun;119(6):1019-1040. doi: 10.1016/j.jfma.2020.04.003. Epub 2020 Apr 29. PMID: 32359879.
45
Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Lin HC, Kao JH, Chuang WL. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020 Jul;119(7):1135-1157. doi: 10.1016/j.jfma.2020.04.002. Epub 2020 Apr 27. PMID: 32354689.
46
Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC. Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. Mol Ther Nucleic Acids. 2020 Jun 5;20:480-490. doi: 10.1016/j.omtn.2020.03.005. Epub 2020 Mar 19. PMID: 32278307; PMCID: PMC7150432.
47
Hong CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, Kao JH, Liu CJ. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. J Microbiol Immunol Infect. 2020 Aug;53(4):569-577. doi: 10.1016/j.jmii.2018.09.005. Epub 2018 Sep 26. PMID: 30316726.
48
Su TH, Tseng TC, Liu CJ, Chou SW, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Kao JH. Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. Int J Cancer. 2020 Aug 1;147(3):901-908. doi: 10.1002/ijc.32840. Epub 2020 Jan 2. PMID: 31853972.
49
Liu CJ, Chen PJ. Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. Viruses. 2020 Jul 28;12(8):815. doi: 10.3390/v12080815. PMID: 32731536; PMCID: PMC7472725.
50
Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses. 2020 Jul 10;12(7):741. doi: 10.3390/v12070741. PMID: 32664198; PMCID: PMC7412310.
